Scotiabank raised the firm’s price target on Sabra Health Care (SBRA) to $20 from $19 and keeps a Sector Perform rating on the shares. Scotiabank notes recent results point to expected move-in pace remaining strong in Spring 2025 and the firm continues to see landlord pricing power since analyses show assisted living screens as more affordable than home care in the majority of REIT markets, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.